BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Cipla Ltd. Makes Cancer Drug Cheaper


5/3/2012 8:04:32 AM

Cipla has launched a copycat version of German pharma company Bayer's cancer medicine Nexavar at one-tenth the price, thumbing its nose again at the pharma multinational by selling drugs at a fraction of the original rates. Cipla's launch of its drug Soranib — used to treat kidney cancer — at Rs 28,000 for a month's dose, comes just a month after Bayer filed a patent infringement case against the company. "How many patients in India can afford Rs 2.8 lakh a month for one medicine?" asked Cipla joint managing director Amar Lulla. Pharma analysts and patient lobbyists welcomed Cipla's move, saying the launch will benefit the country's kidney cancer patients by radically slashing treatment costs. India has nearly 5 lakh cancer patients.


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->